Cartesian Therapeutics, Inc. (RNAC) — 10-Q Filings

10-Q Filings (7)

• Cartesian Therapeutics Files Q1 2026 10-Q — Apr 30, 2026 Risk: low
  Cartesian Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending March 31, 2026. The filing includes financial statements and exhibits
• Cartesian's Q3 Loss Widens Amid Soaring R&D, Cash Dwindles — Nov 6, 2025 Risk: high
  Cartesian Therapeutics, Inc. (RNAC) reported a net loss of $35.902 million for the three months ended September 30, 2025, a significant increase from the $24.18
• Cartesian's Q2 Losses Widen Amid Increased R&D Spend — Aug 7, 2025 Risk: high
  Cartesian Therapeutics, Inc. (RNAC) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company
• Cartesian Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: low
  Cartesian Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key financial
• Cartesian Therapeutics Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Cartesian Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Selecta Biosciences Inc., is incorporated i
• Cartesian Therapeutics Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Cartesian Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Selecta Biosciences Inc., is in the pharmaceutic
• Cartesian Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: low
  Cartesian Therapeutics, Inc. (RNAC) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Cartesian Therapeutics, Inc. filed a 10-Q report for the period

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX